Skip to content

Impact of Exercise Therapy on Functional Capacity in Patients Listed for Liver Transplantation

Impact of Exercise Therapy on Functional Capacity in Patients Listed for Liver Transplantation

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02949505
Enrollment
18
Registered
2016-10-31
Start date
2017-03-01
Completion date
2018-08-01
Last updated
2020-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Cirrhosis, Liver Dysfunction

Keywords

Prehabilitation, liver transplant, functional capacity, exercise

Brief summary

A UK prospective, single-centre feasibility study investigating the effects of exercise therapy on functional capacity in patients on the waiting list for liver transplantation. Patients will receive a 12-week home prehabilitation program (daily step program; functional resistance exercise sessions; telephone health call or virtual clinic). The following will be assessed at weeks 0, 6 and 12 weeks: feasibility (recruitment, compliance, safety, patients perception), functional capacity (ISWT, SPBT), psychological wellbeing (HADS questionnaire) and quality of life (EQ-5D)

Detailed description

as above

Interventions

BEHAVIORALHome prehabilitation program

12-week exercise therapy using daily step program (accelerometer), functional resistance exercise sessions and telephone/virtual clinic appointments

Sponsors

Queen Elizabeth Hospital NHS Foundation Trust
CollaboratorOTHER
Matthew Armstrong
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Meet the United Kingdom Liver Transplant criteria for listing * Accepted on the liver transplant waiting list for a primary transplant * Adults ≥18years who have an indication for a liver transplant * Diagnosed with sarcopenia at liver transplant assessment

Exclusion criteria

* Significant cardiovascular instability including a recent Myocardial infarction, recent Cerebrovascular accident and/or a recent unstable arrhythmia * Unstable encephalopathy - open to interpretation by the chief investigator * Patient or next of kin non-English speaking * Inpatients * Refusal or lacks capacity to give informed consent

Design outcomes

Primary

MeasureTime frameDescription
Number of participants with intervention-related adverse events as assessed by CTCAE v4.012-weekAs this is a feasibility/Pilot study the investigators need to assess if any participants have any adverse events related to the home prehabilitation programme and if so, determine the severity and frequency

Other

MeasureTime frameDescription
Functional capacity - incremental shuttle walk test12-weeksincremental shuttle walk test
Functional capacity - short performance battery test12-weeks
Psychological wellbeing - HADS questionnaire12-weeksHADS questionnaire
Quality of Life - EQ-5D questionnaire12-weeksEQ-5D questionnaire

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026